<DOC>
	<DOC>NCT02228746</DOC>
	<brief_summary>Clinical intervention on overweight or moderately obeses adults. The objective of this trial is to demonstrate the superior eficacy of Alphagos to placebo on weight loss during a low-calorie diet of 12 weeks. The superiority is judged on body weight. Change in cardiometabolic risk factors through the intervention have been evaluated as secondary endpoints</brief_summary>
	<brief_title>Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<criteria>Body Mass Index &gt; or equal 25 and &lt; 35 Use of effective contraception in women of childbearing age Pregnant women (positive pregnancy test) or breastfeeding Antihypertensive or cholesterol treatment HIV infection or HCV Hepatic and/or severe renal failure Heart attack within 6 months prior the selection Heart failure known Inflammatory disease known Cancer or have had cancer within 3 years prior to the study except for basal cell skin cancers Diabetes defined by blood glucose greater than or equal to 1.26 g/L Gastrointestinal disease known Bariatric surgery</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>